Welcome to LookChem.com Sign In|Join Free
  • or
4-(bromomethyl)-2-(3-(2-fluoroethoxy)-4-methoxyphenyl)-5-methylthiazole is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1398230-14-2

Post Buying Request

1398230-14-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1398230-14-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1398230-14-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,8,2,3 and 0 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1398230-14:
(9*1)+(8*3)+(7*9)+(6*8)+(5*2)+(4*3)+(3*0)+(2*1)+(1*4)=172
172 % 10 = 2
So 1398230-14-2 is a valid CAS Registry Number.

1398230-14-2Relevant academic research and scientific papers

DEOXYCYTIDINE KINASE INHIBITORS

-

, (2015/02/25)

Provided herein are compounds that bind to dCK and methods for treating cancer.

Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography

Murphy, Jennifer M.,Armijo, Amanda L.,Nomme, Julian,Lee, Chi Hang,Smith, Quentin A.,Li, Zheng,Campbell, Dean O.,Liao, Hsiang-I.,Nathanson, David A.,Austin, Wayne R.,Lee, Jason T.,Darvish, Ryan,Wei, Liu,Wang, Jue,Su, Ying,Damoiseaux, Robert,Sadeghi, Saman,Phelps, Michael E.,Herschman, Harvey R.,Czernin, Johannes,Alexandrova, Anastassia N.,Jung, Michael E.,Lavie, Arnon,Radu, Caius G.

, p. 6696 - 6708 (2013/10/01)

Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using 18F-L-1-(2′-deoxy-2′-FluoroArabinofuranosyl) Cytosine (18F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = ~1-12 nM) using the 18F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy.

DEOXYCYTIDINE KINASE BINDING COMPOUNDS

-

, (2012/09/22)

The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1398230-14-2